ABSTRACT
The low molecular weight heparin (LMW heparin) compounds are derived by breaking up either enzymatically or chemically the long heparin chains into smaller fragments. They have greater specific antithrombotic activity and less antiplatelet activity. They also have the virtue of being easier to dose and are safer to use. LMW heparin is the treatment of choice over standard heparin for most thrombotic disease.
